|
ESYT1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.08270001245126E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.10519999818592E-08 |
| Normal-vs-Stage2 |
3.625600E-02 |
| Normal-vs-Stage3 |
1.59809999999982E-06 |
| Normal-vs-Stage4 |
2.38389999999145E-05 |
| Stage1-vs-Stage2 |
3.610000E-02 |
| Stage1-vs-Stage3 |
9.185000E-01 |
| Stage1-vs-Stage4 |
5.114600E-01 |
| Stage2-vs-Stage3 |
7.227500E-02 |
| Stage2-vs-Stage4 |
3.347900E-02 |
| Stage3-vs-Stage4 |
5.916600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.92520005387809E-09 |
| Normal-vs-AfricanAmerican |
6.556600E-04 |
| Normal-vs-Asian |
3.88179999999405E-06 |
| Caucasian-vs-AfricanAmerican |
7.129600E-01 |
| Caucasian-vs-Asian |
1.796010E-01 |
| AfricanAmerican-vs-Asian |
5.635600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.17309999999138E-05 |
| Normal-vs-Female |
1.52440005063426E-09 |
| Male-vs-Female |
3.088600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.07150005429691E-09 |
| Normal-vs-Age(41-60Yrs) |
4.21839999997786E-06 |
| Normal-vs-Age(61-80Yrs) |
1.561450E-04 |
| Normal-vs-Age(81-100Yrs) |
9.012600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.377900E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.152000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.400600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.881800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.026400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.489400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.040800E-01 |
| Classical-VS-Follicular |
2.36630004479821E-09 |
| Classical-VS-Other |
1.861930E-02 |
| Classical-VS-Normal |
2.84594570132413E-12 |
| Tall-VS-Follicular |
1.59776999999472E-05 |
| Tall-VS-Other |
7.083600E-03 |
| Tall-VS-Normal |
3.10849999995977E-06 |
| Follicular-VS-Other |
6.932600E-01 |
| Follicular-VS-Normal |
7.359000E-01 |
| Other-VS-Normal |
6.771200E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.35229999999898E-05 |
| Normal-vs-N1 |
4.463900E-03 |
| N0-vs-N1 |
7.244200E-01 |
|
|
